On October 28, the US Department of Health and Human Services told American pharmacies it would stop enforcing the rules that kept them from compounding BPC-157, as long as a list of conditions is met. Within days, social feeds had shortened that to “BPC-157 is legal now.” Three months earlier, the FDA’s own reviewers had sat down and counted the human studies behind the peptide. They needed one hand.
What HHS actually signed
The document is titled HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, and the word that matters is discretion. It covers six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For those six, HHS says it does not intend to take action against a state-licensed pharmacy, a federal facility or a licensed physician that compounds them, provided every condition in the policy is met.
The conditions are not decorative. The bulk powder has to come from an FDA-registered facility with a valid certificate of analysis, and the original manufacturer must be registered with the FDA and compliant with current good manufacturing practice. Serious adverse events go to the FDA’s MedWatch system. Each compounded product may contain a single active ingredient and must be labeled as a compounded drug that is not for resale. Public comments are open until November 13, 2026.
What the policy leaves out is just as telling. It does not add any of the six peptides to the FDA’s list of bulk substances eligible for compounding, and it is not a drug approval. HHS also reserved the right to revisit the whole arrangement if a safety signal or a product-quality problem appears.
The department was candid about its motive. The policy says it is meant to “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers,” while giving patients more choice. Put plainly, Washington built a narrow, documented channel because it wants Americans to stop relying on the undocumented one.
The July vote and the staff who argued against it
The policy followed a meeting of the FDA’s Pharmacy Compounding Advisory Committee on July 23. The panel voted 8 to 6, with one abstention, to recommend BPC-157 for a single evaluated use: ulcerative colitis. FDA career scientists had recommended against it. The vote was advisory, and putting a substance on the bulks list still requires formal notice-and-comment rulemaking. HHS reached instead for enforcement discretion, a tool that does not.
The backstory explains why the staff dug in. In 2023 the FDA placed BPC-157 in Category 2 of its compounding framework, the group reserved for substances that raise significant safety concerns, citing risks that included allergic reactions, kidney damage and tumor growth.
What the FDA found when it counted
The FDA’s briefing document on BPC-157, dated May 11, 2026, is one of the most detailed public reviews of the peptide’s evidence so far. The nominators had proposed several uses, among them Crohn’s disease, celiac disease and tendonitis. The agency evaluated only ulcerative colitis, because it could not identify clinical trials of BPC-157 for any of the others.
For ulcerative colitis, reviewers found a single randomized, placebo-controlled trial, completed by 46 participants. Across every proposed use, the FDA identified five clinical studies that assessed BPC-157’s safety in people. It reviewed 25 non-clinical studies, described the mechanism of action as unknown, and found no human study that used the routes of administration the nominators were actually proposing. Staff summarized the efficacy question in one line, citing a “lack of evidence to support the effectiveness” of BPC-157 for the one disease under review.
Part of the human record barely reached print at all. A 2005 meeting abstract in Gastroenterology by Ruenzi and colleagues described a trial of the compound, then coded PL 14736, in patients with active ulcerative colitis. The full study was never published.
An independent check lands in the same place. A 2025 systematic review in the HSS Journal by Vasireddi and colleagues gathered 36 studies on BPC-157’s musculoskeletal effects published between 1993 and 2024. Thirty-five were preclinical. One involved people: a retrospective review in which 7 of 12 patients with chronic knee pain reported relief lasting more than six months. The authors noted that there is no clinical safety data in humans.
None of this proves BPC-157 does nothing. The animal literature is large, much of it traces back to the University of Zagreb group that first characterized the peptide, and those animal signals are the reason the nominations happened at all. What the record shows is a gap between animal promise and human proof, and a committee vote cannot close it.
Why “legal again” is the wrong way to read it
Enforcement discretion is a conditional promise not to act, and it can be withdrawn. It does not turn BPC-157 into an approved drug, and it does not bless the research market. The memo’s own logic runs the other way: it demands registered manufacturing, certificates of analysis and adverse-event reporting because, in HHS’s view, much of the material Americans were buying online came with none of those guarantees. Anyone treating the policy as a blanket endorsement has read it backwards.
There is a real argument on the policy’s side. Its defenders say Americans were already buying these peptides online, and that a licensed pharmacy using registered, tested material is safer than an anonymous parcel. Its critics, including FDA reviewers and the consumer group Public Citizen, which testified against BPC-157 in July, answer that a cleaner supply chain does not make an unproven drug proven. Both points can be true at once, which is exactly why the headline version of the story misleads.
Sport has not moved either. The World Anti-Doping Agency still lists BPC-157 as a prohibited substance, whatever pharmacies may now do.
What reaches Costa Rica: no law, one useful yardstick
None of this changes the legal picture in Costa Rica. An HHS enforcement policy binds US regulators and US pharmacies. Medicines in Costa Rica answer to the Ministerio de Salud, and a memo written in Washington does not alter its rules. Readers looking for BPC-157 in Costa Rica will still find it sold as a laboratory research material, a separate category from a medicine with a separate set of obligations.
Local suppliers that take that distinction seriously say so in plain terms. The FAQ at peptidescostarica.net, for instance, states that its products are not registered with the Ministerio de Salud as pharmaceuticals and that it provides no dosing guidance, protocols or medical advice. That is the honest position for a research supplier, and it is worth more than a recycled headline about American pharmacies.
The October memo still hands Costa Rican researchers something practical: a yardstick. Of its conditions, the one any buyer can check from a desk is the certificate of analysis. For a fifteen-residue peptide with the sequence GEPPPGKPADDAGLV and a molecular weight of roughly 1,419, a credible certificate does two separate jobs. Mass spectrometry confirms the molecule is the right one, and HPLC reports how much of the sample is that molecule. A certificate that shows a purity figure with no identity result answers only half the question. Peptides Costa Rica publishes its batch certificates in a public database, so a buyer can match the paperwork to the vial before anything is opened.
Two smaller checks help as well: the batch number on the certificate should match the one printed on the vial, and the test date should be recent enough to describe the material actually on the shelf.
What happens next
The comment period closes on November 13. The FDA may still propose adding some or all of the six peptides to the bulks list through rulemaking, a process that can run for months or years, and HHS has said it may revisit the policy if safety or quality problems surface.
Policies can change in an afternoon. The human evidence file on BPC-157 is five studies thick, and it will stay that thin until someone runs proper trials and publishes the results.
